Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

NCM and ImaginAb to commercialize Zr-89

New York City-based PET radiopharmaceutical development company NCM USA announced this month that ImaginAb will be working on labeling zirconium-89 (Zr-89) and manufacturing practice in a new long-term contract with NCM. 

UT Austin produces alternative means of enriching targets

The University of Texas Austin announced yesterday that a new method for enriching targets for medical isotopes has been developed and patented.

Thumbnail

Breast Imaging market could rise to $3B by 2019

A market report on breast imaging technologies published this month by research firm Markets and Markets forecasts growth in breast imaging to approximately $3 billion in the next five years.

Moving past monetary incentive: Repurposing approved drugs for Alzheimer's

There may be drugs at the industry's fingertips, already approved, that could be of value in treating patients with neurodegenerative disease if repurposed and brought to regulatory approval for expanded indications, but these may be stalled due to rundown patents and a lack of financial incentive in the market, according the a study published June 24 in the Annals of Clinical and Translational Neurology.

Super Bowl champion becomes AAN spokesperson for TBI awareness

The American Academy of Neurology (AAN) and the American Brain Foundation announced yesterday that they have named former NFL champion Ben Utecht an official, nationwide spokesperson for the AAN. Utecht will now be charged with advocating awareness of sports concussions and their dangers.

Thumbnail

International Academy of Cardiology Annual Scientific Sessions 2014

The 19th world congress on heart disease organized by the International Academy of Cardiology will be covering the cutting edge of cardiovascular research, including molecular and cellular cardiology, from July 25-28 at the Hyatt Regency Boston.

Lantheus Holdings announces filing of registration statement for proposed initial public offering

Lantheus Holdings, parent company to Lantheus Medical Imaging, a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol "LNTH." The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

Anti-amyloid therapy being developed to combat Alzheimer’s memory loss

An investigational amyloid antibody treatment called solanezumab is being evaluated by Northwestern University School of Medicine and Rush University Medical Center in Chicago for its efficacy in slowing memory loss caused by Alzheimer's disease.